Top

Current Fungal Infection Reports

Published in:

01-12-2018 | Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Emergence of Resistance to Fluconazole in Candida albicans Isolated From Vaginal Discharge

Authors: Susana Córdoba, Constanza Taverna, Walter Vivot, Wanda Szusz, Matias Vivot, Guillermina Isla, Graciela Davel

Published in: Current Fungal Infection Reports | Issue 4/2018

Abstract

Purpose of Review

To provide information about the emergence of fluconazole resistance in Candida albicans isolated from vaginal discharge, in a global context, and to update the in vitro susceptibility profile of this species from Argentina.

Recent Findings

Vulvovaginal candidiasis is the second most common vaginal infection after vaginal bacteriosis. C. albicans remains the prevalent etiological yeast species, and despite antifungal treatment, the rate of recurrence remains high, which may be associated to antifungal resistance.

Summary

Data here presented were obtained from the study of C. albicans strains isolated from patients with clinical signs of vulvovaginal candidiasis from 1996 to 2017. Data obtained could represent the susceptibility profile of C. albicans strains circulating in Argentina and could be of potential usefulness to monitor and guide therapy, and also suggests the need for greater surveillance programs to detect fluconazole resistance over time.

Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol. 2011;37:250–61. https://doi.org/10.3109/1040841X.2011.576332.CrossRefPubMed

Negroni R, Arechavala AI, Bianchi MH, Robles AM. Problemas clínicos en Micología Médica: problema no. 33. Rev Iberoam Micol. 2008;25:196–8.CrossRef

Sherrard J, Donders G, White D, Jensen JS. European (IUSTI/WHO) guideline on the management of vaginal discharge. 2011. Int J STD AIDS. 2011;22:421–9. https://doi.org/10.1258/ijsa.2011.011012.CrossRefPubMed

Kalkanci A, Güzel AB, Jabban II, Aydin M, Ilkit M, KusTimur S. Candida vaginitis in nonpregnant patients: a study of antifungal susceptibility testing and virulence factors. J Obstet Gynaecol. 2013;33:378–83. https://doi.org/10.3109/01443615.2013.767323.CrossRefPubMed

Mendling W, Brasch J, Guideline vulvovaginal candidosis. (2010)of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55(Suppl 3):1–13. https://doi.org/10.1111/j.1439-0507.2012.02185.x.CrossRefPubMed

Matheson A, Mazza D. Recurrent vulvovaginal candidasis: a review of guideline recommendations. Aust N Z J Obstet Gynaecol. 2017;57:139–45.CrossRef

Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15–21. https://doi.org/10.1016/j.ajog.2015.06.067.CrossRefPubMed

Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003;110:66–72.CrossRef

Fan SR, Liu XP, Li JW. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res. 2008;34:561–6. https://doi.org/10.1111/j.1447-0756.2008.00817.x.CrossRefPubMed

10.

Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17:340–5 9.CrossRef

11.

Aballea S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel JD, et al. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.CrossRef

12.

•• Bader O. Fungal species identification by MALDI-ToF mass spectrometry. Methods Mol Biol Clifton NJ. 2017;1508:323–37 Describes the usefulness of this technique to identify fungal species. CrossRef

13.

Romeo O, Criseo G. Candida africana and its closest relatives. Mycoses. 2010;54:475–86.CrossRef

14.

Croxatto A, Prod’hom G, Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev. 2012;36:380–407.CrossRef

15.

Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 1995;141:1507–21. https://doi.org/10.1099/13500872-141-7-1507.CrossRefPubMed

16.

Sampath A, Weerasekera M, Dilhari A, Gunasekara C, Bulugahapitiya U, Fernando N, et al. Comparison of duplex PCR and phenotypic analysis in differentiating Candida dubliniensis from Candida albicans from oral samples. AMB Express. 2017;7:141. https://doi.org/10.1186/s13568-017-0435-9.CrossRefPubMedPubMedCentral

17.

Shan Y, Fan S, Liu X, Li J. Prevalence of Candida albicans-closely related yeasts, Candida Africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol. 2014;52:636–40. https://doi.org/10.1093/mmy/myu003.CrossRefPubMed

18.

Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani I, Nabili M, et al. Molecular characterization of highly susceptible Candida africana from vulvovaginal candidiasis. Mycopathologia. 2015;180:317–23. https://doi.org/10.1007/s11046-015-9924-z.5.CrossRefPubMed

19.

• Hazirolan G, Altun HU, Gumral R, Gursoy NC, Otlu B, Sancak B. Prevalence of Candida africana and Candida dubliniensis, in vulvovaginal candidiasis: first Turkish Candida africana isolates from vulvovaginal candidiasis. J Mycol Med. 2017;27:376–81. https://doi.org/10.1016/j.mycmed.2017.04.106 Describes cryptic species that belong to Candida albicans species complex. CrossRefPubMed

20.

• Theill L, Dudiuk C, Morano S, Gamarra S, Nardin ME, Méndez E, et al. Prevalence and antifungal susceptibility of Candida albicans and its related species Candida dubliniensis and Candida africana isolated from vulvovaginal samples in a hospital of Argentina. Rev Argent Microbiol. 2016;48:43–9 Describes cryptic species that belong to Candida albicans species complex and their antifungal susceptibility profile. PubMed

21.

•• Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of Candidiasis 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50. https://doi.org/10.1093/cid/civ933 Current Guideline for antifungal treatment. CrossRefPubMed

22.

Watson C, Pirotta M. Recurrent vulvovaginal candidiasis: current management. Aust Fam Physician. 2011;40:149–51.PubMed

23.

Miró MS, Rodríguez E, Vigezzi C, Icely PA, Gonzaga de Freitas Araújo M, Riera FO, et al. Vulvovaginal candidiasis: an old disease with new challenges. Rev Iberoam Micol. 2017;34:65–71.CrossRef

24.

White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11:382–402.CrossRef

25.

Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis. 2009;64(3):354–6. https://doi.org/10.1016/j.diagmicrobio.2009.03.021.CrossRefPubMed

26.

Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120:1407–14. https://doi.org/10.1097/AOG.0b013e31827307b2.CrossRefPubMed

27.

Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction-impact of two decades. Mycoses. 2011;54(1):34–8. https://doi.org/10.1111/j.1439-0507.2009.01752.x.CrossRefPubMed

28.

Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J. 2016;129:1161–5.CrossRef

29.

Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist. 2018;11:447–56. https://doi.org/10.2147/IDR.S153116 eCollection 2018.CrossRefPubMedPubMedCentral

30.

Feng LJ, Wan Z, Wang XH, Li RY, Liu W. Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene. Chin Med J. 2010;123:544–8.PubMed

31.

Chen LM, Xu YH, Zhou CL, Zhao J, Li CY, Wang RJ. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. Int Med Res. 2010;38(2):536–45.CrossRef

32.

Zhao J, Xu Y, Li C. Association of T916C (Y257H) mutation in Candida albicans ERG11 with fluconazole resistance. Mycoses. 2013;56:315–20.CrossRef

33.

•• Liu JY, Shi C, Wang Y, Li WJ, Zhao Y, Xiang MJ. Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. Res Microbiol. 2015;166:153–61 Describes the molecular mechanisms of fluconazole resistance. CrossRef

34.

•• Khosravi Rad K, Falahati M, Roudbary M, Farahyar S, Nami S. Overexpression of MDR-1 and CDR-2 genes in fluconazole resistance of Candida albicans isolated from patients with vulvovaginal candidiasis. Curr Med Mycol. 2016;2(4):24–9 Describes the molecular mechanisms of fluconazole resistance. CrossRef

35.

Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis. 2010;66(4):373–84. https://doi.org/10.1016/j.diagmicrobio.2009.11.006.CrossRefPubMed

36.

Zhang JY, Liu JH, Liu FD, Xia YH, Wang J, Liu X, et al. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses. 2014;57(10):584–91. https://doi.org/10.1111/myc.12204.CrossRefPubMed

37.

INDEC. https://www.indec.gob.ar.

38.

Riera FO, Caeiro JP, Denning D. Burden of serious fungal infections in Argentina. J Fungi (Basel). 2018;4(2):E51. https://doi.org/10.3390/jof4020051.CrossRef

39.

García Heredia M, García SD, Copolillo EF, Eliseth MC, Barata AD, Vay CA, et al. Prevalencia de candidiasis vaginal en embarazadas. Identificación de levaduras y sensibilidad a los antifúngicos. Rev Argent Microbiol. 2006;38:9–12.PubMed

40.

Arechavala AI, Bianchi MH, Robles AM, Santiso G, Negroni R. Identificación y sensibilidad frente a fluconazol y albaconazol de 100 cepas de levaduras aisladas de flujo vaginal. Rev Iberoam Micol. 2007;24:305–8.CrossRef

41.

Gamarra S, Morano S, Dudiuk C, Mancilla E, Nardin ME, de Los Angeles Méndez E, et al. Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. Mycopathologia. 2014;178(3–4):251–8. https://doi.org/10.1007/s11046-014-9780-2.CrossRefPubMed

42.

Muccia MJ, Cuestas ML, Landanburu MF, Mujica MT. Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. Rev Iberoam Micol. 2017;34:72–6.CrossRef

43.

Scocozza L, Azula N, Córdoba S, Smayevsky J, Relloso MS. High level of fluconazol resistance in Candida spp. isolated from vaginal specimens in adults women in a Universitary Hospital in Buenos Aires, Argentina. Int J Infect Dis. 2018;73S:276. https://doi.org/10.1016/j.ijid.2018.04.4045.CrossRef

44.

•• Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Hamal P, Guinea J, and the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST. Definitive document E.DEF 7.3.1. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. January 2017. http://www.eucast.org. Reference document used in the present study.

Title: Emergence of Resistance to Fluconazole in Candida albicans Isolated From Vaginal Discharge
Authors: Susana Córdoba
Constanza Taverna
Walter Vivot
Wanda Szusz
Matias Vivot
Guillermina Isla
Graciela Davel
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 4/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0329-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Emergence of Resistance to Fluconazole in Candida albicans Isolated From Vaginal Discharge

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Correction to: Pressing Priorities for Mycetoma Control and Prevention

Diagnosing Invasive Mold Infections: What Is Next

Association of Malassezia to Atopic Dermatitis

Cryptococcosis in Patients with Hematologic Diseases

Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders

The Southern Endemic Zone of Paracoccidioidomycosis: Epidemiological Approach in Northeast Argentina

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page